BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 7492818)

  • 1. [Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan].
    Bonneterre J
    Bull Cancer; 1995 Aug; 82(8):623-8. PubMed ID: 7492818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trials with the topoisomerase I inhibitors.
    Burris HA; Rothenberg ML; Kuhn JG; Von Hoff DD
    Semin Oncol; 1992 Dec; 19(6):663-9. PubMed ID: 1334279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined topoisomerase I inhibition for the treatment of metastatic colon cancer.
    Holcombe RF; Kong KM; Wimmer D
    Anticancer Drugs; 2004 Jul; 15(6):569-74. PubMed ID: 15205598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topoisomerase I inhibitors in the treatment of colorectal cancer.
    Rothenberg ML; Blanke CD
    Semin Oncol; 1999 Dec; 26(6):632-9. PubMed ID: 10606256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical and phase I trials of topoisomerase I inhibitors.
    Von Hoff DD; Burris HA; Eckardt J; Rothenberg M; Fields SM; Chen SF; Kuhn JG
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S41-5. PubMed ID: 8070026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Camptothecin analogues: studies from the Johns Hopkins Oncology Center.
    Slichenmyer WJ; Rowinsky EK; Grochow LB; Kaufmann SH; Donehower RC
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S53-7. PubMed ID: 7520844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials].
    Couteau C; Yakendji K; Terret C; Goncalves E; Armand JP
    Bull Cancer; 1996 Jan; 83(1):3-10. PubMed ID: 8672854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Topoisomerase inhibitors developing in Japan].
    Furue H
    Gan To Kagaku Ryoho; 1993 Jan; 20(1):42-9. PubMed ID: 8422186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.
    Gerrits CJ; de Jonge MJ; Schellens JH; Stoter G; Verweij J
    Br J Cancer; 1997; 76(7):952-62. PubMed ID: 9328159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The development of camptothecin analogs in childhood cancers.
    Bomgaars L; Berg SL; Blaney SM
    Oncologist; 2001; 6(6):506-16. PubMed ID: 11743213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I clinical trial of weekly combined topotecan and irinotecan.
    Lokich J
    Am J Clin Oncol; 2001 Aug; 24(4):336-40. PubMed ID: 11474256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
    Rowinsky EK; Grochow LB; Ettinger DS; Sartorius SE; Lubejko BG; Chen TL; Rock MK; Donehower RC
    Cancer Res; 1994 Jan; 54(2):427-36. PubMed ID: 8275479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An overview of topoisomerase I-targeting agents.
    Arbuck SG; Takimoto CH
    Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology.
    Vassal G; Pondarré C; Boland I; Cappelli C; Santos A; Thomas C; Lucchi E; Imadalou K; Pein F; Morizet J; Gouyette A
    Biochimie; 1998 Mar; 80(3):271-80. PubMed ID: 9615866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [DNA topoisomerase inhibitor].
    Sugiura T; Ariyoshi Y
    Gan To Kagaku Ryoho; 1992 Nov; 19(13):2140-5. PubMed ID: 1332623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
    Rowinsky EK; Grochow LB; Hendricks CB; Ettinger DS; Forastiere AA; Hurowitz LA; McGuire WP; Sartorius SE; Lubejko BG; Kaufmann SH
    J Clin Oncol; 1992 Apr; 10(4):647-56. PubMed ID: 1312588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical use of topoisomerase I inhibitors in anticancer treatment.
    Rodriguez-Galindo C; Radomski K; Stewart CF; Furman W; Santana VM; Houghton PJ
    Med Pediatr Oncol; 2000 Oct; 35(4):385-402. PubMed ID: 11025469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topoisomerase I inhibitors. An overview of the camptothecin analogs.
    Burris HA; Fields SM
    Hematol Oncol Clin North Am; 1994 Apr; 8(2):333-55. PubMed ID: 8040144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topoisomerase I inhibitors: review and update.
    Rothenberg ML
    Ann Oncol; 1997 Sep; 8(9):837-55. PubMed ID: 9358934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.
    Mathijssen RH; Loos WJ; Verweij J; Sparreboom A
    Curr Cancer Drug Targets; 2002 Jun; 2(2):103-23. PubMed ID: 12188913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.